SkinBioTherapeutics plc (LON:SBTX – Get Free Report) hit a new 52-week low during mid-day trading on Monday. The company traded as low as GBX 4.50 and last traded at GBX 4.71, with a volume of 190,895 shares traded. The stock had previously closed at GBX 5.
SkinBioTherapeutics Stock Performance
The stock’s 50 day moving average price is GBX 6.57 and its 200 day moving average price is GBX 9.77. The company has a debt-to-equity ratio of 11.77, a quick ratio of 10.01 and a current ratio of 6.14. The company has a market capitalization of £12.18 million, a P/E ratio of -29.38 and a beta of 0.10.
SkinBioTherapeutics Company Profile
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
See Also
- Five stocks we like better than SkinBioTherapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
